EUVIMEDEUVIMED entdecken
Crossref

GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors

Rushin Patel, Mark Wadid, Bhargav Makwana, Ashish Kumar, Sumanth Khadke, Ammar Bhatti, Ahan Banker, Zaid Husami, Sherif Labib, David Venesy, Gregg Fonarow, Mikhail Kosiborod und 6 weitere

JACC: Heart Failure · 2024

DOI: 10.1016/j.jchf.2024.07.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Rushin Patel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Diabetes Mellitus, Type 2, Stroke Volume. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with obesity and heart failure with preserved ejection fraction (HFpEF) has demonstrated improvement in cardiovascular outcomes, the incremental benefits of GLP-1 RA for patients already on sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain underexplored. OBJECTIVES: This study aimed to assess the incremental benefits of GLP-1 RA in patients with type 2 diabetes mellitus, overweight/obesity, and HFpEF receiving SGLT2i therapy. METHODS: The authors conducted a retrospective cohort study using the TriNetX research database including patients ≥18 years with type 2 diabetes mellitus, body mass index ≥27 kg/m2, and HFpEF on SGLT2i. Two cohorts were created based on GLP-1 RA prescription. The outcomes were heart failure exacerbation, all-cause emergency department visits/hospitalizations among others over a 12-month period. RESULTS: A total of 7,044 patients remained in each cohort after propensity score matching. There was a significantly lower risk of heart failure exacerbations, all-cause emergency department visits/hospitalizations, new-onset atrial arrhythmias, new-onset acute kidney injury, and pulmonary hypertension in the GLP-1 RA plus SGLT2i cohort compared with the SGLT2i-only cohort. The associated benefits persisted across different body mass indexes and ejection fractions as well as in patients with elevated natriuretic peptide. The risk of diabetic retinopathy was higher in the combination therapy group than with SGLT2i-only use. CONCLUSIONS: GLP-1 RA, in addition to SGLT2i, was associated with a significantly lower risk of heart failure hospitalizations in this patient population, suggesting a potential incremental benefit. This highlights the need for prospective studies to confirm the clinical benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureDiabetes Mellitus, Type 2Stroke VolumeObesityOverweightGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedHospitalizationHypoglycemic Agents

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2isheart failure with preserved ejection fractionobesityoverweight

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.
  • Department of Internal Medicine, Cleveland Clinic Akron General Hospital, Cleveland, Ohio, USA.
  • Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California-Los Angeles, Los Angeles, California, USA.
  • Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
  • Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Cardiovascular Center, Houston, Texas, USA.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Zitieren

APA

Patel, R., Wadid, M., Makwana, B., Kumar, A., Khadke, S., Bhatti, A., Banker, A., Husami, Z., Labib, S., Venesy, D., Fonarow, G., Kosiborod, M., Al-Kindi, S., Bhatt, D. L., Dani, S., Nohria, A., Butler, J., & Ganatra, S. (2024). GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.07.006

Vancouver

Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, et al. GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2024.07.006

BibTeX
@article{Patel2024,
  author = {Patel, Rushin and Wadid, Mark and Makwana, Bhargav and Kumar, Ashish and Khadke, Sumanth and Bhatti, Ammar and Banker, Ahan and Husami, Zaid and Labib, Sherif and Venesy, David and Fonarow, Gregg and Kosiborod, Mikhail and Al-Kindi, Sadeer and Bhatt, Deepak L and Dani, Sourbha and Nohria, Anju and Butler, Javed and Ganatra, Sarju},
  title = {GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors},
  journal = {JACC: Heart Failure},
  year = {2024},
  doi = {10.1016/j.jchf.2024.07.006}
}
Kostenlos starten →